All posts tagged ross camidge

  • First-line use of Alectinib potential new standard of care for ALK-positive non-small cell lung cancer

    Results of a 303-patient, multi-national phase III clinical trial known as ALEX published today in NEJM and presented concurrently at ASCO 2017 argue for alectinib replacing crizotinib as first-line standard of care in advanced ALK-positive non-small cell lung cancer.